
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor Thrasyvoulos Tzellos is Dermatologist at the Department of Dermatology, NLSH Bodø, Norway, and Associate Professor at Institute of Clinical Medicine, University of Tromsø, Norway.
Professor Tzellos received his medical degree from the Aristotle University of Thessaloniki, Greece, moving on to complete an MSc in Clinical Research and Epidemiology and a PhD from the same institution. He has also completed several postgraduate courses on educational techniques, epidemiology and clinical pharmacology in healthcare.
He has published over 100 peer-reviewed articles and his current research expertise lies in the field of evidence-based medicine, clinical trials, meta-analyses, case-control studies, cohort studies and large-scale epidemiological studies. He is actively involved in clinical research on hidradenitis suppurativa and is a founding member of the European Hidradenitis Suppurativa Foundation (EHSF).
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.